These big-cap technology companies could be bargains worth buying.
Shock waves from a competitor's stumble sent the clinical-stage biotech's shares reeling.
European regulators have signed off on the biotech's revolutionary gene therapy for beta-thalassemia.
These top healthcare stocks could be worth adding to portfolios if the market sells off sharply.
The sky-high price of this revolutionary new gene therapy may not be as crazy as it seems.
The company is riding high following FDA clearance for its tattoo removal medical device.
Sales are soaring at this marijuana stock, but rising revenue isn't the only thing you should know about its performance last quarter.
The latest trial results for its hemophilia A gene therapy suggest it may eliminate or significantly reduce the need for weekly infusions.
Increasing demand for its forecasting software is sending sales soaring.
A $2.1 million price tag could make Zolgensma a blockbuster medicine for these companies.
These biotech stocks could pop or drop next month following ASCO's annual conference.
The clinical-stage developer of RNAi therapies is being added to the S&P 600 index.
Berkshire Hathaway is the single largest shareholder of these well-known companies.
Berkshire Hathaway sold these stocks last quarter, and that could mean you should sell them, too.
Here's which one of these large-cap biotechs put up the best numbers in the first quarter.
These were Berkshire Hathaway's biggest buys in the first quarter.
The price slipped on news of a share offering by one of its biggest investors.
Cannabis company Tilray's latest financial report includes plenty of pros and cons.
Canada's second-biggest marijuana stock by revenue is growing rapidly, but losses continue.
CannTrust's got big plans that could turn it into one of Canada's top pot stocks.